abvc-logo-nasdaq-440x386 (1).png
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 26, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Reverse Stock Split
July 24, 2023 12:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
July 06, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
June 26, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
June 20, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
June 12, 2023 08:30 ET | ABVC BioPharma, Inc.
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
June 06, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
May 22, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
May 04, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
April 26, 2023 08:30 ET | ABVC BioPharma, Inc.
Fremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...